首页|阿托伐他汀钙结合非诺贝特药物治疗冠心病的临床价值

阿托伐他汀钙结合非诺贝特药物治疗冠心病的临床价值

扫码查看
目的 分析阿托伐他汀钙结合非诺贝特药物治疗冠心病(CHD)的临床价值.方法 选取CHD患者 82 例,按随机数字表法分为联合组(n=41)和单一组(n=41),单一组予以阿托伐他汀钙治疗,联合组在单一组基础上结合非诺贝特治疗.对比两组疗效、血脂水平[总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)]、颈动脉内膜中层厚度(IMT)、血管内皮功能[一氧化氮(NO)、血管内皮素-1(ET-1)]、心功能[左心室收缩末期内径(LVESD)、左室射血分数(LVEF)]水平及不良反应发生率.结果 联合组总有效率 95.12%(39/41)较单一组 80.49%(33/41)高(P<0.05);治疗后,联合组TC、TG水平较单一组低,HDL-C水平较单一组高(P<0.05);治疗后,联合组颈动脉IMT水平较单一组低(P<0.05);治疗后,联合组ET-1 水平较单一组低,NO水平较单一组高(P<0.05);治疗后,联合组LVEF水平较单一组高,LVESD水平较单一组低(P<0.05);两组不良反应对比差异无统计学意义(P>0.05).结论 对CHD患者采用非诺贝特联合阿托伐他汀钙治疗,可提高疗效,能降低血脂水平和颈动脉IMT厚度,并可改善血管内皮功能和心功能,安全性可靠.
Clinical Value of Atorvastatin Calcium Combined with Fenofibrate in the Treatment of Coronary Atherosclerotic Heart Disease
Objective To analyze the clinical value of atorvastatin calcium combined with fenofibrate in the treatment of coronary atherosclerotic heart disease(CHD).Methods A total of 82 cases of CHD patient were selected and divided into a combination group(n=41)and a single group(n=41)by random number table method.The single group was treated with ator-vastatin calcium,and the combined group was treated with fenofibrate on the basis of a single group.The therapeutic effect,blood lipid levels[total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),triglyceride(TG)],carotid intimax-media thickness(IMT),vascular endothelial function[nitric oxide(NO),endothelin-1(ET-1)],cardiac function[left ventricular end-systolic diameter(LVESD),and left ventricular ejection fraction(LVEF)]were compared between the two groups Number and the incidence of adverse reactions.Results The total effective rate of the combination group95.12%(39/41)was higher than that of the single group 80.49%(33/41)(P<0.05).After treatment,the TC and TG levels in the combination group were lower than those in the single group,and the HDL-C level was higher than those in the single group(P<0.05).After treatment,the level of carotid IMT in the combination group was lower than that in the single group(P<0.05).After treatment,the ET-1 lev-el in the combination group was lower than that in the single group,and the NO level was higher than that in the single group(P<0.05).After treatment,the LVEF level in the combination group was higher than that in the single group,and the LVESD level was lower than that in the single group(P<0.05).There was no significant difference in adverse reactions be-tween the two groups(P>0.05).Conclusion Fenofibrate combined with atorvastatin calcium in the treatment of CHD patients can improve the efficacy,reduce the blood lipid levels and carotid IMT thickness,and improve the vascular endothelial func-tion and cardiac function,which is safe and reliable.

Atorvastatin calciumFenofibrateCoronary atherosclerotic heart diseaseCardiac function

侯宾、郑方方

展开 >

平顶山市第二人民医院心血管内二科,河南 平顶山 467000

阿托伐他汀钙 非诺贝特 冠心病 心功能

2024

哈尔滨医药
哈尔滨市医学会

哈尔滨医药

影响因子:0.697
ISSN:1001-8131
年,卷(期):2024.44(1)
  • 12